Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Messenger ribonucleic acid (mRNA)-based drugs, notably mRNA vaccines, have been
widely proven as a promising treatment strategy in immune therapeutics. The extraordinary …

Abstract mRNA vaccines represent a promising alternative to conventional vaccine
approaches because of their high potency, capacity for rapid development and potential for …

Cancer is characterized by an accumulation of genetic alterations. Somatic mutations can
generate cancer-specific neoepitopes that are recognized by autologous T cells as foreign …

Cancer vaccines, which are designed to amplify tumour-specific T cell responses through
active immunization, have long been envisioned as a key tool of effective cancer …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

Clinical trials with immune checkpoint inhibitors have provided important insights into the
mode of action of anticancer immune therapies and potential mechanisms of immune …

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous
dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC) …

mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has
potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in …

T-lymphocytes play a critical role in cancer immunity as evidenced by their presence in
resected tumor samples derived from long-surviving patients, and impressive clinical …